Effective FIP treatment

One capsule every 12 hours, for every 2.5 kg of body weight. Capsules can be administer either on an empty stomach or with meal. If vomiting occurs within 30 minutes, administer another dosage.

Molnupiravir EIDD-1931 is not recommended for: cats with neurological or ocular FIP symptoms. cats with digestive problems. cats in critical conditions. cats with preexisting liver or kidney conditions. when treatments exceed 60 days.

Avoid the following medications: CYP Enzyme Inhibitors: Certain antifungals (e.g., ketoconazole) Antibiotics (e.g., erythromycin) Other medications (e.g., ritonavir) CYP Enzyme Inducers: Rifampin Certain antiepileptics (e.g., phenytoin) Medications Affecting Renal Excretion: NSAIDs Certain diuretics Some antibiotics (e.g., aminoglycosides) Drugs That Prolong the QT Interval: Certain antipsychotics Antiarrhythmics Antibiotics like macrolides and fluoroquinolones Other Antiviral Drugs: Careful evaluation is needed to avoid antagonistic effects or increased toxicity.

On average, cats under EIDD-1931 treatment experience 97% success rate in treatment by adhering to our prescribed treatment protocol of 1 capsule every 12 hours for every 2.5kg of body weight. Consult your veterinarian before deviating from our recommended treatment protocol.

Yes, EIDD-1931 medication is conveniently encapsulated in soft gel capsules . Simply place the capsule behind your cat's tongue or mix it with cat food for easy administration.

FIP is a fatal disease in cats with no chance of natural recovery. Cats diagnosed with FIP typically reach a critical condition within a week due to the disease's rapid progression, and without treatment, it is invariably fatal. The cost of a full GS-441524 treatment course in the United States is high, excluding veterinary fees.However, molnupiravir EIDD-1931 offers a more effective and affordable solution for this devastating condition. This treatment is 4.4x more effective than EIDD-2801 and 7.3x more effective than GS-441524, ensuring rapid recovery with significant improvement seen within a week. It also has lower cytotoxicity, making it safer for prolonged use, and boasts a near-zero relapse rate, providing lasting peace of mind. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114919/#:~:text=FIP%20is%20a%20fatal%20immune,found%20in%20cats%20%5B4%5D.

EIDD-1931 treatment is not suitable for all FIP infections. Cats exhibiting ocular or neurological symptoms, are in critical conditions, lacking appetite, or have pre-existing liver and kidney conditions should start with 2-4 weeks of GS-441524 injections, or until these conditions are resolved before using EIDD-1931. To purchase GS-441524 visit: https://www.curefip.com

Yes, EIDD-1931 has been used as cure and proven to be highly effective in treating FIP through various university and independent clinical studies. In these studies EIDD-1931 has demonstrated 4.4x higher efficacy than Molnupiravir (EIDD-2801) and 7.3x higher efficacy than GS-441524. In these clinical trials cats demonstrated significant recovery within a week of treatment, with a near-zero relapse rate and less side effects than Molnupiravir (EIDD-2801), making it a safe and reliable treatment option for feline infectious peritonitis. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227765/

Pharmaceutical drug EIDD-2801, commercially known as Molnupiravir is a prodrug commonly used to treat COVID-19 in humans. Upon ingestion by humans or animals, EIDD-2801 is converted by the body into its active form, EIDD-1931. Clinical researches conducted in the USA and China have shown that EIDD-1931 offered by Molnufip.com is 4.4 times more potent than EIDD-2801 and does not require the body to make the conversion. Additionally, EIDD-1931 exhibits 33% lower cytotoxicity in in vitro tests. Cytotoxicity often leads to undesired and sometimes hard to manage side effects. These findings suggest that EIDD-1931 is a safer and more effective option for treating FIP than Molnupiravir due to its higher potency and lower cytotoxicity.

According to the clinical study published on the National Institutes of Health (USA), 46.2% of cats exhibit clinical signs of improvement within the first week, 84.6% within two weeks, and 92% by the third week. This is a good representation of real world treatment results. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612227/

No, EIDD-1931 treatment is recommended for a maximum of 60 days. Generally recommended treatment regiment begins with a 30 day treatment. If symptoms persist, continue with another 30 days of treatment. Consult your veterinarian if symptoms persist after 60 days of treatment and switch to GS-441524 injectable or oral treatment solutions.

MolnuFIP™ EIDD-1931 is most effective for early to mid-stage FIP. EIDD-1931 is especially effective for Wet Form of feline infectious peritonitis. Cats with digestive problems, or are in late stages of infection, exhibiting neurological and ocular symptoms, should start FIP treatment with GS-441524 injections. You can purchase GS-441524 from reputable vendors such as CUREFIP.COM (globally) or BASMIFIP.COM (only in SE Asia). You can transition to EIDD-1931 once your cat's condition stabilises.

Yes, it is the most cost effective treatment against FIP available today. A 30 days treatment course starts from $39, which is approximately 10x cheaper than alternative FIP treatments GS-441524.

No, avoid drugs known to prolong the QT interval, such as certain antipsychotics, antiarrhythmics, and antibiotics like macrolides and fluoroquinolones, as they may pose a risk when taken with Molnupiravir EIDD-1931.

EIDD-1931, is a mutagenic antiviral drug created by Emory Institute of Drug Development. It is related to Molnupiravir that are use to treat Covid 19 in humands and FIP in cats. EIDD-1931 garnered public attention in early 2023 following a series of independent clinical studies conducted by researchers and real world treatments conducted by veterinarians worldwide. These studies and treatments demonstrated EIDD-1931's effectiveness against feline infectious peritonitis (FIP).

EIDD-1931

Yes, avoid combining MolnuFIP™ EIDD-1931 with soda tablets, sodium bicarbonate, hydroxide tablets, sucralfate, and other alkaline treatments during the treatment period.

Combining antiviral drugs can lead to antagonistic effects or increased toxicity. Consult your veterinarian before using other antivirals in combination with EIDD-1931.

MolnuFIP™ EIDD-1931 is suitable for both effusive (wet) and non-effusive (dry) types of FIP infections. EIDD-1931 arrest FIPV replications, and destroy the underlying cause of FIP only. Cats with fever, loss of appetite, ascites, pleural effusion, diarrhea, jaundice, should seek additional treatments for each of the symptoms.

Store MolnuFIP™ EIDD-1931 in a dry, cool place away from sunlight. Refrigeration is not need. The shelf life is 2 years.

The pharmacokinetics of MolnuFIP™ EIDD-1931 are as follows: C_max: 5.49 ± 0.90 µg/ml T_max: 2.00 ± 1.10 h T_1/2: 4.83 ± 0.72 h AUC_0-t: 38.88 ± 3.92 mg/ml * h

MolnuFIP™ Treatment provides 60 size #3 capsules in each package. Each capsule contains 15 mg of EIDD-1931. Non active excipients includes zeolite, magnesium stareate.

Yes, avoid NSAIDs, certain diuretics, and some antibiotics (e.g., aminoglycosides) as they can impact the renal excretion of EIDD-1931.

The expiration period for MolnuFIP™ EIDD-1931 is 24 months.

EIDD-1931 was developed by Emory Institute for Drug Development, hence the acronym EIDD. Link: https://eidd.emory.edu/

Up to 60 days or as recommended by a veterinarian.

MolnuFIP™ EIDD-1931 is packaged as 60 soft gel capsules in a vacuum-sealed mylar bag.

No, avoid CYP enzyme inhibitors like certain antifungals (e.g., ketoconazole), antibiotics (e.g., erythromycin), and other medications (e.g., ritonavir), as well as CYP inducers such as rifampin and certain antiepileptics (e.g., phenytoin). These can affect the metabolism of EIDD-1931.

Our EIDD-1931 is provided in size #3 capsules with off white powder, easy for ingestion by cats without struggle or regurgitation.

EIDD-1931 is a ribonucleoside analog that incorporates itself into viral RNA during replication, causing mutations that inhibit viral replication (lethal mutagenesis).

MolnuFIP™ EIDD-1931 comes in easy-to-use tiny (size #3) soft gel capsules that can be swallowed whole or mixed with cat food, or administered directly. Cats will regurgitate the pills when administered at the back of tongues, making it far easier to use than non-coated tablets which are often regurgitated shortly after administration.

EIDD-1931 is 4.4x more potent and 3x less cytotoxic than EIDD-2801. In layman terms, it is both more effective and cause less drug related complications than EIDD-2801, making it the preferred choice for FIP treatments by veterinary professionals.

While every cat recovers at different speed due to various factores such as gravity of FIP infection, age, genetic disposition, breed, pre-existing conditions and body vitality, visitable recovery for most cats starts within the first 2 weeks. A minimum of 30 days of treatment is recommended to avoid relapse after termination of treatment.

MolnuFIP™ EIDD-1931 is significantly more effective and safer than EIDD-2801. EIDD-1931 is 4x more potent and has 3.3x lower cytotoxicity, making it far better suited for FIP treatment in cats. While EIDD-2801 is often used for FIP treatment due to its wide availability, EIDD-1931 offers more superior efficacy and fewer short and long term side effects, ensuring a more successful and simpler treatment for your cat.

Our EIDD-1931 has shown 97% treatment success rate in FIP treatments when following our prescribed treatment regiment of 1 capsules for every 2.5kg of body weight, every 12 hours. Avoid using EIDD-1931 for cats with neurological and ocular symptoms, digestive problems, liver or kidney problems, or in critical condition. Use GS-441524 injections until above issue are resolved before switching to EIDD-1931. Stop using EIDD-1931 when treatment length extend beyond 60 days. In such cases, use GS-441524 injections to treat FIP infections.

No, there is no known drug resistance to EIDD-1931 due to its potency and short treatment length.